SARC038

June 24, 2021

Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

TYPE OF SARCOMA: Osteosarcoma
DRUG: Regorafenib, Nivolumab

ACCRUAL STATUS: Not recruiting

OVERALL STUDY PRINCIPAL INVESTIGATORS:
Fariba Navid, MD
Children’s Hospital of Los Angeles

Lara Davis, MD
Oregon Health and Sciences University

CLINICALTRIALS.GOV IDENTIFIER: NCT04803877 

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Navid’s SARC038 presentation at the 2021 SARC Semiannual Meeting:

To contact the study research staff:

CONTACT SARC


Back to top